(Reuters) -INmune Bio said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with ...

Novo Nordisk (NVO) and Eli Lilly & Co. (NYSE:LLY), the global leaders in obesity medications, are now facing their first ...

Lifestyle therapy may not be enough to improve outcomes for patients with HF and obesity, but careful risk evaluation and ...

Lone Pine Capital’s Q1 2025 13F portfolio value dropped to $11.58B, with holdings reduced from 30 to 22, focusing on top tech ...

Although anti-calcitonin gene-related peptides are safe and efficacious for adolescents with chronic migraine, access to ...

The post Big, Beautiful Bill Finds Its Opponents appeared first on Reason.com.

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...

A federal judge has rejected Johnson & Johnson’s challenge to block its proposed rebate model under the 340B Drug Pricing Program, Bloomberg Law reported June 27. Judge Rudolph Contreras of the U.S.

The S&P 500 rose by 0.52% on Friday to close at a record high of 6,173.07, marking returns of 3.44% for the week, as traders ...

Total adverse events of heart failure or all-cause mortality were reduced with empagliflozin, regardless of kidney function.

Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their ...

China NMPA approves Innovent’s mazdutide, first dual GCG/GLP-1 receptor agonist for chronic weight management: San Francisco, US Monday, June 30, 2025, 12:00 Hrs [IST] Innovent ...